Peritoneal mesotheioma. Cytoreductive surgery and HIPEC

Background. Peritoneal mesothelioma is a rare, high invasive and aggressive malignant tumor that arises from the mesothelial cells lining the abdominal cavity. Surgery is a primary treatment method for mesothelioma. It allows the removal of macroscopically visible tumor masses, which are often resistant to conventional drug therapy. However, the necessity and appropriateness of a surgical approach should be assessed individually, taking into account the histological subtype of the tumor, the extent of its spread and the presence of associated risk factors. Current research shows that the best long-term results are achieved with a multimodal treatment approach, which may include a combination of surgery, chemotherapy, and radiotherapy. This comprehensive approach allows for more effective management of the disease and improved quality of life of patients. Case report . We present a clinical case of a 59year-old female patient with peritoneal mesothelioma. The patient underwent surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and doxorubicin. During a 12-month follow-up, there were no signs of disease progression, which indicates the high effectiveness of the applied approach. Conclusion. The use of cytoreductive surgery and HIPEC demonstrated positive effects in the treatment of peritoneal mesothelioma.